Effector Therapeutics Inc (EFTR) — Cash Flow Quality Index
Effector Therapeutics Inc (EFTR) has a Cash Flow Quality Index of -2.12x as of March 2022. Operating cash flow of $-6.50 Million is below net income of $3.07 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Effector Therapeutics Inc cash conversion from operations to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Effector Therapeutics Inc Cash Flow Quality Index (2020–2021)
Historical Cash Flow Quality Index for Effector Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Effector Therapeutics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Effector Therapeutics Inc (2020–2021)
Year-by-year earnings quality comparison for Effector Therapeutics Inc. For live market cap and the full company financial profile, see EFTR stock market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | -1.58x | $-24.89 Million | $15.80 Million | ▼ -261.8% |
| 2020 | 0.97x | $13.84 Million | $14.21 Million | — |